Sage Faces Multiple Moments Of Truth For Zuranolone, GABA Modulation
Parkinson’s Data For NMDA Modulator Also On Tap Before Year’s End
Before pivotal depression data in 2021 attempt to redeem zuranolone after a failed Phase III study, the company will report Phase II results for next-gen GABA modulator SAGE-324 in essential tremor.
You may also be interested in...
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.